We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for eculizimab (Soliris) (Alexion Pharmaceuticals Australasia Pty Ltd)
Active ingredients
eculizimab (Soliris)
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution for intravenous infusion
Indication
Treatment of patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti aquaporin 4 antibody positive
Therapeutic area
Neurology